Quantinno Capital Management LP Boosts Stock Position in Fulgent Genetics, Inc. $FLGT

Quantinno Capital Management LP raised its holdings in Fulgent Genetics, Inc. (NASDAQ:FLGT) by 374.7% during the first quarter, Holdings Channel reports. The institutional investor owned 137,479 shares of the company’s stock after buying an additional 108,519 shares during the period. Quantinno Capital Management LP’s holdings in Fulgent Genetics were worth $2,186,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Fulgent Genetics by 2,984,354.9% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,522,072 shares of the company’s stock valued at $39,985,000 after acquiring an additional 1,522,021 shares during the last quarter. RTW Investments LP purchased a new stake in Fulgent Genetics during the fourth quarter worth approximately $18,521,000. JPMorgan Chase & Co. boosted its holdings in Fulgent Genetics by 767.0% in the third quarter. JPMorgan Chase & Co. now owns 299,014 shares of the company’s stock valued at $6,758,000 after purchasing an additional 264,524 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Fulgent Genetics by 89.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 348,533 shares of the company’s stock valued at $9,156,000 after purchasing an additional 164,535 shares during the last quarter. Finally, Wells Fargo & Company MN increased its stake in Fulgent Genetics by 261.1% in the fourth quarter. Wells Fargo & Company MN now owns 120,781 shares of the company’s stock valued at $3,173,000 after purchasing an additional 87,329 shares during the last quarter. 48.06% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently weighed in on FLGT. Weiss Ratings restated a “sell (e+)” rating on shares of Fulgent Genetics in a research report on Monday, July 6th. Piper Sandler lifted their price target on shares of Fulgent Genetics from $15.00 to $19.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 4th. Finally, Wall Street Zen cut shares of Fulgent Genetics from a “sell” rating to a “strong sell” rating in a research report on Saturday. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $27.50.

Insider Buying and Selling

In other Fulgent Genetics news, insider Hanlin Gao sold 1,688 shares of Fulgent Genetics stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $17.89, for a total value of $30,198.32. Following the sale, the insider owned 990,374 shares of the company’s stock, valued at approximately $17,717,790.86. The trade was a 0.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Jian Xie sold 2,146 shares of the stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $17.89, for a total value of $38,391.94. Following the transaction, the chief operating officer directly owned 367,605 shares of the company’s stock, valued at approximately $6,576,453.45. This trade represents a 0.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 5,980 shares of company stock worth $106,360 in the last ninety days. 36.18% of the stock is owned by corporate insiders.

Fulgent Genetics Stock Performance

Shares of FLGT opened at $19.06 on Tuesday. The stock has a market capitalization of $524.34 million, a P/E ratio of -6.76 and a beta of 0.91. Fulgent Genetics, Inc. has a 1 year low of $13.46 and a 1 year high of $31.04. The company’s fifty day moving average is $19.39 and its two-hundred day moving average is $18.78.

Fulgent Genetics (NASDAQ:FLGT) last issued its earnings results on Thursday, July 30th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.12). Fulgent Genetics had a negative net margin of 26.05% and a negative return on equity of 4.93%. The firm had revenue of $85.39 million during the quarter, compared to analysts’ expectations of $94.00 million. Fulgent Genetics has set its FY 2026 guidance at -2.350–2.220 EPS. Sell-side analysts predict that Fulgent Genetics, Inc. will post -2.81 EPS for the current year.

Fulgent Genetics Profile

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.